SCHEMBL696549

SCHEMBL696549

[O]CCc1ccc(SC(F)(F)F)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRZ1 P23471 4/20 0.57
PTPN1 P18031 2/20 0.57
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
EPHX2 P34913 1/20 0.42
NR1H4 Q96RI1 1/20 0.42
KIF11 P52732 1/20 0.39
KCNK2 O95069 4/20 0.37
KCNK10 P57789 3/20 0.37
MAPT P10636 1/20 0.36
ATM Q13315 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
ALKBH5 Q6P6C2 1/20 0.35
FTO Q9C0B1 1/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
TRPV1 Q8NER1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6001747 0.87 PTPRZ1 (0.65) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL95318 0.83 PTPRZ1 (0.61) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL3630994 0.79 PTPRZ1 (0.57) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL5537909 0.79 PTPRZ1 (0.57) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL13064734 0.79 PTPRZ1 (0.57) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL1161025 0.79 KDM4E (0.59) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL22105757 0.78 PTPRZ1 (0.61) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL18998006 0.78 PTPRZ1 (0.65) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL5544527 0.76 PTPRZ1 (0.53) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL10655803 0.76 ALDH1A1 (0.52) PTPRZ1PTPN1ALDH1A1KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421847-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS Janssen Pharmaceutica N.V. (BE) 2012-02-29 EP claimed
US-20110015171-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2011-01-20 US claimed
WO-2010124116-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-10-28 WO claimed
US-8623858-B2 Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-01-07 US disclosed
US-20130123233-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (US) 2013-05-16 US disclosed
EP-2421847-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS Janssen Pharmaceutica N.V. (BE) 2012-02-29 EP disclosed
US-20110015171-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2011-01-20 US disclosed
WO-2010124116-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015171-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA PTPRZ1 600/4885PTPN1 1550/4885ALDH1A1 364/4885
US-20130123233-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA PTPRZ1 600/4885PTPN1 1550/4885ALDH1A1 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.